Importantly, however, a combinatorial approach of targeting PTP4A3 with PRL3‐zumab, which has already been shown effective in mice and currently is in Phase II trials (NCT04452955), alongside current generation, clinically used chemotherapeutic drugs (5‐fluorouracil, cisplatin and paclitaxel) could be an effective strategy for treating KRAS mutant, HGSOC cancers. This evidence concerns the gene PTP4A3 and cancer.